Presentation is loading. Please wait.

Presentation is loading. Please wait.

Renee C. Gresh, DO, E. Anders Kolb, MD, Corinna L

Published byOscar Verbeke Modified over 5 years ago

Similar presentations

Presentation on theme: "Renee C. Gresh, DO, E. Anders Kolb, MD, Corinna L"— Presentation transcript:

1 Progression of Cerebral Vascular Disease Post Transplant in a Child with Prior Sickle Cell Disease 
Renee C. Gresh, DO, E. Anders Kolb, MD, Corinna L. Schultz, MD, MSHP, Vinay Kandula, MD, Joseph H. Piatt, MD, FAAP, Emi Caywood, MD, Robin Miller, MD  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, Pages S222-S223 (February 2015) DOI: /j.bbmt Copyright © Terms and Conditions

2 Biology of Blood and Marrow Transplantation 2015 21, S222-S223DOI: (10
Biology of Blood and Marrow Transplantation  , S222-S223DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Biology of Blood and Marrow Transplantation 2015 21, S222-S223DOI: (10
Biology of Blood and Marrow Transplantation  , S222-S223DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Renee C. Gresh, DO, E. Anders Kolb, MD, Corinna L"

Similar presentations

Utilization and Outcome of Bone Marrow Transplantation in Children with Sickle Cell Disease: A Pediatric Health Information System Database Analysis 

Utilization and Outcome of Bone Marrow Transplantation in Children with Sickle Cell Disease: A Pediatric Health Information System Database Analysis 
Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.
Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,
Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant  Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant  Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.

Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.
Microsoft Access®: A Viable Blood and Marrow Transplant (BMT) Database Solution  Lindsay Dozeman, Alison Amendola, MHA, Connie Grobe, Lisa Cantwell, MHA,

Microsoft Access®: A Viable Blood and Marrow Transplant (BMT) Database Solution  Lindsay Dozeman, Alison Amendola, MHA, Connie Grobe, Lisa Cantwell, MHA,
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation  Filippo Milano, MD, PhD, Brent.

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation  Filippo Milano, MD, PhD, Brent.
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.
Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.
Case Report: 52 Year-Old Male 11 Months after MUD for Angionimmunoblastic T Cell Lymphoma Developed Acute Fibrinous Organizing Pneumonitis Successfully.

Case Report: 52 Year-Old Male 11 Months after MUD for Angionimmunoblastic T Cell Lymphoma Developed Acute Fibrinous Organizing Pneumonitis Successfully.
Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 

Similar presentations

Ads by Google